Ovarian Cancer
Conditions
Interventions
Experimental group:nab-paclitaxel in combination with carboplatin
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Women aged 18-80 years. 2. Patients with epithelial ovarian cancer/tubal cancer/primary peritoneal cancer confirmed by pathology in our hospital. 3. FIGO stage was stage III-IV. 4. Initial tumor cell reduction was performed, which was evaluated as incomplete tumor reduction after surgery, and albumin-bound paclitaxel + carboplatin adjuvant chemotherapy was performed. 5. ECOG score: 0-2; Life expectancy >3 months; No obvious abnormalities in organ function: (1) Liver function: total bilirubin = 60ml/min; (3) Blood function: neutrophils >= 3x10^9/L; Platelet count >= 80x10^9/L, hemoglobin >= 7g/dL. 6. Patients give informed consent to the basic contents of the study, and can complete the treatment as planned and continue to follow up. 7. There is no history of other malignancies that may interfere with the comparison of treatment or study effectiveness.
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding patients. 2. Inability to give informed consent to research content and interventions. 3. Preoperative neoadjuvant chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year progression-free survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| chemotherapy related adverse events;incidence of post-operative complications;quality of life; | — |
Countries
China
Contacts
Public ContactLinghu Hua
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed